Originally published as JCO Early Release 10.1200/JCO.2006.09.7030 on December 8 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ozols, R. F. Articles by Winn, R. J. Search for Related Content PubMed PubMed Citation Articles by Ozols, R. F. Articles by Winn, R. J. Social Bookmarking                            What's this?

Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

Robert F. Ozols^*, Roy S. Herbst^*, Yolonda L. Colson^**, Julie Gralow^**, James Bonner, Walter J. Curran, Jr, Burton L. Eisenberg, Patricia A. Ganz, Barnett S. Kramer, Mark G. Kris, Maurie Markman, Robert J. Mayer, Derek Raghavan, Gregory H. Reaman, Raymond Sawaya, Richard L. Schilsky, Lynn M. Schuchter, John W. Sweetenham, Linda T. Vahdat, Rodger J. Winn

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to Todd Bentsen, American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: bentsent{at}asco.org

A MESSAGE FROM ASCO’s PRESIDENT For the second consecutive year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant cancer research presented or published over the past year.

ASCO developed this report to demonstrate the enormous progress being made on the front lines of cancer research today. The report is intended to give all those with an interest in cancer care—the general public, cancer patients and physicians, policymakers, oncologists, and other medical professionals—an accessible summary of the year's most important cancer research advances.

These pages report on new targeted therapies that are improving survival and response rates in hard-to-treat cancers such as kidney cancer, HER-2–positive breast cancer, head and neck cancer, and chronic myelogenous leukemia; the FDA’s approval of the world's first preventive vaccine for human papillomavirus (HPV), which has the potential to dramatically reduce the global burden of cervical cancer; and advances in the fast-growing field of personalized medicine, including a new lung cancer test that could help physicians better target treatments and predict prognosis.

These advances are only part of the landscape. Survival rates are on the rise, the number of cancer deaths in the United States began declining for the first time since 1930, and new research is showing that the rates of certain common cancers, such as those of the breast and colon, have stabilized, and may have even begun to decline.

However, cancer research still faces a number of major obstacles. At a time of extraordinary scientific potential, declining federal funding of cancer research threatens to stall or even reverse recent progress. Such funding cuts have already led to fewer clinical trials, fewer talented young physicians entering the field, and a growing bottleneck of basic science discoveries waiting to be "translated" into useful therapies and diagnostics. In addition to highlighting the major research advances over the past year, this report also identifies key barriers to accelerating the pace of cancer research and outlines ASCO's recommendations for overcoming them.

Despite these and other challenges, there is much good news on the front lines of cancer research. This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat, diagnose, and prevent a group of diseases that strike half of men and one-third of women in the United States. I want to thank the Editorial Board members, the Specialty Editors, and the ASCO Cancer Communications Committee and Cancer Research Committee for their dedicated work to develop this report. I hope you find it useful.

Sincerely,

Gabriel N. Hortobagyi, MD, FACP

President

American Society of Clinical Oncology

published online ahead of print at www.jco.org on December 8, 2006.

^* Executive Editor/Editorial Board

^** Editorial Board

Specialty Editor

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. M. Dilts, A. Sandler, S. Cheng, J. Crites, L. Ferranti, A. Wu, R. Gray, J. MacDonald, D. Marinucci, and R. Comis Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group Clin. Cancer Res., June 1, 2008; 14(11): 3427 - 3433. [Abstract] [Full Text] [PDF]

				D. Breen and F. Barlesi The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 805 - 811. [Abstract] [Full Text] [PDF]

				J. Ji, A. Forsti, J. Sundquist, P. Lenner, and K. Hemminki Survival in Bladder and Renal Cell Cancers Is Familial J. Am. Soc. Nephrol., May 1, 2008; 19(5): 985 - 991. [Abstract] [Full Text] [PDF]

				S. Boeck, T. Hoehler, G. Seipelt, R. Mahlberg, A. Wein, A. Hochhaus, H.-P. Boeck, B. Schmid, E. Kettner, M. Stauch, et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer Ann. Onc., February 1, 2008; 19(2): 340 - 347. [Abstract] [Full Text] [PDF]